Thomas Stinchcombe Discusses Immunotherapy Breakthroughs for Lung Cancer

Article

Immunotherapies have strong potential as a treatment option for patients with NSCLC, as clinical trials have shown dramatic and durable results.

Thomas Stinchcombe, co-director of the multidisciplinary thoracic oncology program at the University of North Carolina at Chapel Hill, shares the potential of immunotherapies in non-small cell lung cancer (NSCLC).

Stinchcombe says immunotherapies have strong potential as a treatment option for patients with NSCLC, as clinical trials have shown dramatic and durable results.

Immunotherapies will hopefully become a new option for patients with NSCLC in the near future, Stinchcombe predicts, adding there is a higher tolerance in terms of side effects.

Because EGFR and ALK mutations are often found in a smaller group of patients, immunotherapies can possibly apply to a broader spectrum of patients.

Related Videos
Dr. Andrea Apolo in an interview with CURE
Dr. Kim in an interview with CURE
Dr. Nguyen, from Stanford Health, in an interview with CURE
Dr. Barzi in an interview with CURE
Sue Friedman in an interview with CURE
Dr. Giles in an interview with CURE